"The voice for cancer physicians and their patients in Massachusetts."

  • Home
  • Resources
  • FDA Approvals
  • FDA GRANTED REGULAR APPROVAL TO THE COMBINATION OF RITUXIMAB AND HYALURONIDASE HUMAN (RITUXAN HYCELA, GENENTECH) FOR ADULT PATIENTS WITH FOLLICULAR LYMPHOMA

FDA GRANTED REGULAR APPROVAL TO THE COMBINATION OF RITUXIMAB AND HYALURONIDASE HUMAN (RITUXAN HYCELA, GENENTECH) FOR ADULT PATIENTS WITH FOLLICULAR LYMPHOMA

23 Jun 2017 8:23 AM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration granted regular approval to the combination of rituximab and hyaluronidase human (Rituxan Hycela, Genentech) for adult patients with follicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia. Read full press release. 

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software